

# Daniel Pink

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1073765/publications.pdf>

Version: 2024-02-01

65  
papers

4,893  
citations

293460

24  
h-index

124990

64  
g-index

74  
all docs

74  
docs citations

74  
times ranked

5639  
citing authors

#	ARTICLE	IF	CITATIONS
1	Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study. <i>Supportive Care in Cancer</i> , 2022, 30, 187-196.	1.0	10
2	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa). <i>British Journal of Cancer</i> , 2022, 126, 1346-1354.	2.9	6
3	FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel — results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. <i>European Journal of Cancer</i> , 2022, 165, 48-57.	1.3	15
4	FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2—Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 3750-3761.	0.8	28
5	Transferability of Health-Related Quality of Life Data of Large Observational Studies to Clinical Practice: Comparing Retroperitoneal Sarcoma Patients from the PROSa Study to a TARPS-WG Cohort. <i>Oncology Research and Treatment</i> , 2022, 45, 660-669.	0.8	2
6	Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective <sc>QOLIXANE</sc> trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. <i>International Journal of Cancer</i> , 2021, 148, 1478-1488.	2.3	13
7	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. <i>Oncology Research and Treatment</i> , 2021, 44, 301-312.	0.8	13
8	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Cancers, 2021, 13, 1223.	1.7	15
9	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). <i>European Journal of Cancer Care</i> , 2021, 30, e13484.	0.7	7
10	Does rehabilitation pose a risk to patients suffering from haemato-oncological diseases? Results of a monocentric, retrospective analysis in Germany. <i>European Journal of Cancer Care</i> , 2020, 29, e13201.	0.7	3
11	1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma. <i>Annals of Oncology</i> , 2020, 31, S899.	0.6	17
12	1669TiP A non-randomized, open-label phase II trial evaluating efficacy and feasibility of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas (STS) after failure of an anthracycline-containing regimen. <i>Annals of Oncology</i> , 2020, 31, S991.	0.6	1
13	1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma— Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. <i>Annals of Oncology</i> , 2020, 31, S901.	0.6	6
14	1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction — Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO. <i>Annals of Oncology</i> , 2020, 31, S908.	0.6	6
15	1495P FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel — Final results from the phase II RAMIRIS Study of the AIO. <i>Annals of Oncology</i> , 2020, 31, S928.	0.6	3
16	1525O The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry. <i>Annals of Oncology</i> , 2020, 31, S939.	0.6	0
17	1533P Real-life data from the platform for outcome, quality of life and translational research on pancreatic cancer - PARAGON. <i>Annals of Oncology</i> , 2020, 31, S943.	0.6	0
18	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of a Nationwide Observational Study (PROSa). <i>Cancers</i> , 2020, 12, 3590.	1.7	31

#	ARTICLE	IF	CITATIONS
19	Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO) Tj ETQq1 1 0.784314zgBT /Over	0.7	14
20	Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). International Journal of Cancer, 2020, 147, 2493-2502.	2.3	22
21	Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO. Annals of Oncology, 2019, 30, v321.	0.6	0
22	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, The, 2019, 393, 1948-1957.	6.3	1,494
23	FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO.. Journal of Clinical Oncology, 2019, 37, 4023-4023.	0.8	4
24	No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation. Transplant Infectious Disease, 2018, 20, e12822.	0.7	5
25	Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.. Journal of Clinical Oncology, 2018, 36, 11570-11570.	0.8	2
26	Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2067-2076.	1.2	8
27	Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib. JAMA Oncology, 2017, 3, 602.	3.4	141
28	A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology, 2017, 28, v228.	0.6	1
29	A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).. Journal of Clinical Oncology, 2017, 35, 4-4.	0.8	16
30	Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients. BMC Cancer, 2016, 16, 619.	1.1	15
31	Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma. International Journal of Hyperthermia, 2016, 32, 159-164.	1.1	5
32	Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1091-1097.	1.2	4
33	Metastatic Potential of Grade I Chondrosarcoma of Bone: Results of a Multi-institutional Study. Annals of Surgical Oncology, 2016, 23, 120-125.	0.7	42
34	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology, 2016, 34, 244-250.	0.8	174
35	Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG). Marine Drugs, 2015, 13, 379-388.	2.2	9
36	Radioembolization in Patients with Progressive Gastrointestinal Stromal Tumor Liver Metastases Undergoing Treatment with Tyrosine Kinase Inhibitors. Journal of Vascular and Interventional Radiology, 2015, 26, 231-238.	0.2	17

#	ARTICLE	IF	CITATIONS
37	Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma. <i>British Journal of Cancer</i> , 2015, 112, 455-460.	2.9	12
38	Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4152-TPS4152.	0.8	16
39	Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis. <i>Oncology</i> , 2014, 87, 95-103.	0.9	37
40	Prognostic relevance of 18F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF- $\alpha$ and melphalan. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1076-1083.	3.3	12
41	Differentiation of myxoid liposarcoma by magnetic resonance imaging: a histopathologic correlation. <i>Acta Radiologica</i> , 2014, 55, 952-960.	0.5	29
42	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. <i>Cancer</i> , 2014, 120, 2325-2333.	2.0	65
43	Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. <i>British Journal of Cancer</i> , 2014, 110, 1155-1162.	2.9	42
44	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>European Journal of Cancer</i> , 2013, 49, 1027-1031.	1.3	69
45	Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread—results of a large prospective trial. <i>Annals of Oncology</i> , 2013, 24, 1400-1405.	0.6	64
46	Efficacy of Trabectedin in Patients with Advanced or Metastatic Alveolar Soft-Part Sarcoma. <i>Onkologie</i> , 2012, 35, 249-252.	1.1	14
47	One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1265.	3.8	832
48	Survival and prognostic factors in chondrosarcoma. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2011, 82, 749-755.	1.2	122
49	Molecular Targeted Therapy of Gastrointestinal Stromal Tumors. <i>Current Cancer Drug Targets</i> , 2011, 11, 688-697.	0.8	20
50	Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. <i>Annals of Oncology</i> , 2011, 22, 1828-1833.	0.6	43
51	Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. <i>British Journal of Surgery</i> , 2010, 97, 1854-1859.	0.1	185
52	A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 5910-5916.	3.2	101
53	Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 1109-1113.	1.9	142
54	Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx <sup>®</sup> ) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. <i>European Journal of Cancer</i> , 2006, 42, 2303-2309.	1.3	10

#	ARTICLE	IF	CITATIONS
55	Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature. <i>Gynecologic Oncology</i> , 2006, 101, 464-469.	0.6	164
56	Polyclonal Resistance in Gastrointestinal Stromal Tumor Treated with Sequential Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2006, 12, 6206-6206.	3.2	9
57	Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2006, 12, 1743-1749.	3.2	351
58	Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 494-501.	0.8	107
59	Severe Hypoglycemia Caused by Paraneoplastic Production of IGF-II in Patients With Advanced Gastrointestinal Stromal Tumors: A Report of Two Cases. <i>Journal of Clinical Oncology</i> , 2005, 23, 6809-6811.	0.8	59
60	An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. <i>Investigational New Drugs</i> , 2003, 21, 481-486.	1.2	22
61	Chemotherapy in alveolar soft part sarcomas. <i>European Journal of Cancer</i> , 2003, 39, 1511-1516.	1.3	111
62	Acute Hypokalemic Tetraparesis Induced by Intravenous Methotrexate. <i>Journal of Clinical Oncology</i> , 2003, 21, 1896-1897.	0.8	7
63	Extravasations of Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2003, 21, 4068-4069.	0.8	28
64	Oral Trofosfamide: An Active and Well-Tolerated Maintenance Therapy for Adult Patients with Advanced Bone and Soft Tissue Sarcomas. Results of a Retrospective Analysis. <i>Oncology Research and Treatment</i> , 2002, 25, 541-546.	0.8	15
65	Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma. <i>JAMA Oncology</i> , 0, , .	3.4	17